AC Immune Reports Progress
AC Immune reported that ACI-19764 reached the cerebrospinal fluid around the brain and dose-dependently suppressed the inflammatory signal IL-1β in blood analysis. On August 20, AC Immune published interim data from the first cohorts of the ACI-19764 study in healthy volunteers. The company checked if the drug reached the central nervous system environment, achieved the necessary concentration there, and was associated with a biochemical response in the blood.
The ACI-19764 is an orally administered small chemical compound. AC Immune is developing it as an NLRP3-inflammasome inhibitor - an intracellular complex of the immune system involved in the formation of inflammatory signals, including IL-1β. In the August 20 release, the company reported on cohorts with single and repeated doses. The detection of ACI-19764 in cerebrospinal fluid shows that the drug reached the central nervous system environment.
Daily doses of up to 10 mg gave concentrations above the IC90 level - the level of substance that in a laboratory test suppresses 90% of the chosen response. In whole blood samples, IL-1β release decreased with increasing dose. These measurements answer different questions: did the drug reach the central nervous system environment, is its concentration sufficient for the laboratory goal, and does IL-1β release in the blood decrease with dose. The original protocol in the NCT07463196 registry is designed for 78 healthy volunteers.
🔗 Read original →
PubMed Central (PMC)
First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor
This first‐in‐human study evaluated the safety, tolerability, single‐ and multiple‐dose pharmacokinetic profiles with dietary influence, and pharmacodynamics (PD) of DFV890, an oral NLRP3 inhibitor, in healthy participants. In total, 122 ...
August 23, 2026 6
